Leiden University Medical Center, University of Copenhagen in Denmark and Murdoch Children’s Research Institute in Australia
Regenerative Medicine Leiden (RML) is a unique infrastructure built on a collaborative network of outstanding experts and facilities in Leiden with the specific aim to support cell and gene therapy innovations.
The RML infrastructure is strengthened by reNEW - a tripartite partnership between the LUMC, University of Copenhagen in Denmark, and Murdoch Children’s Research Institute in Australia. This is a long-term (10 year) strategic partnership funded by the Novo Nordisk Foundation.
Our goal is to enable generation of cutting-edge, , safe, and sustainable therapies. This is based on the fundamental, translational and clinical science made possible by the RML’s infrastructure and the international collaborative network of excellence of reNEW.
To ensure success, RML places great emphasis on giving researchers in the Netherlands and abroad access to our state-of-the-art facilities and infrastructure, which consists of:
Leiden hiPSC center (https://www.lumc.nl/en/research/facilities/lumc-hipsc-hotel/) – Service includes isolation of somatic cells, reprogramming with state of the art vectors and basic characterisation of pluripotency / generation of isogenic control hiPSCs using CRISPR/Cas9 technology / access to validated differentiation protocols and extensively characterized control hiPSCs (LUMC20 and LUMC99 cell lines) / annual training courses on hiPSC cultivation and differentiation. Service or acquisition costs apply.
Center for Cell and Gene Therapy (https://www.lumc.nl/en/research/facilities/lumc-center-for-cell-and-gene...) and close relations with NecstGen (https://necstgen.com) – Services include expertise in translational drug development and manufacturing of new innovative drugs for clinical use / manufacturing, release and scaling services under Good Manufacturing Practices (GMP) / rental of grade A, B, and C clean rooms / advice and training. Service and/or facility rental costs apply.
Facility for Proteomics and Metabolomics (https://www.lumc.nl/en/research/facilities/facility-for-proteomics-and-m...) – Service includes support with / rental of state-of-the-art Metabolomics and Mass Spectrometry Imaging (M&MSI) systems, sample preparation and analysis methodologies to perform Proteomics (identification and characterization of proteins) / Metabolomics (identification and characterization of metabolites and lipids) / Glycomics (identification and characterization of sugar chains) / Mass Spectrometry Imaging (combining imaging with the analytical properties of MS) / Bioinformatics (handling and analysis of MS data). Service and/or facility rental costs apply.
Light and Electron Microscopy (https://www.lumc.nl/en/research/facilities/light-and-electron-microscopy/) - Imaging facility with access to and support with high-end microscopy systems for live cell, multispectral, and high-resolution imaging / data storage support / image analysis support as Imaris and Huygens platforms software / sharing expertise regarding sample preparation and imaging modalities. Service and/or facility rental costs apply.
Flow Cytometry Core Facility (https://www.lumc.nl/en/research/facilities/flow-cytometry-core-facility/) – The facility provides centralized services including access to instruments (Cytek Aurora, BD Fortessa, BD LSR II, BD FACSLyric, BD FACSCanto II, CBD FACSAria III cell sorters, Fluidigm CyTOF Mass Cytometer) / support for instrument use / testing and acquisition of instruments / leading expertise / education and training. Service and/or facility rental costs apply.
Additionally, RML can help coordinate access to facilities at the other reNEW nodes (overview shown below), including:
With access to these facilities RML aims to boost fundamental science and facilitate the translation of cell and gene therapies into therapeutic and diagnostic applications. RML not only promotes regenerative medicine and stem cell-based research, we also strengthen the pathways from scientific discovery to targeted results and commercialization. The global collaborative network of excellence in targeted biomedical research allows for the exchange of and access to knowledge, data, technologies, systems and methodologies on a broad range of research topics based on organ systems and disease.
